The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 7 of the 21 sources its claims cite were checked for support.
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: The comparative clinical benefit of nonstatin therapies that reduce low-density lipoprotein cholesterol (LDL-C) remains uncertain. OBJECTIVE: To evaluate the association between lowering LDL-C and relative cardiovascular risk reduction across different statin and nonstatin therapies. DATA SOURCES AND STUDY SELECTION: The MEDLINE and EMBASE databases were searched (1966-July 2016). The key inclusion criteria were that the study was a randomized clinical trial and the reported clinical outcomes included myocardial infarction (MI). Studies were excluded if the duration was less than 6 months or had fewer than 50 clinical events. Studies of 9 different types of LDL-C reduction approaches were included. DATA EXTRACTION AND SYNTHESIS: Two authors independently extracted and entered data into standardized data sheets and data were analyzed using meta-regression. MAIN OUTCOMES AND MEASURES: The relative risk (RR) of major vascular events (a composite of cardiovascular death, acute MI or other acute coronary syndrome, coronary revascularization, or stroke) associated with the absolute reduction in LDL-C level; 5-year rate of major coronary events (coronary death or MI) associated with achieved LDL-C level. RESULTS: A total of 312 175 participants (mean age, 62 years; 24% women; mean baseline LDL-C level of 3.16 mmol/L [122.3 mg/dL]) from 49 trials with 39 645 major vascular events were included. The RR for major vascular events per 1-mmol/L (38.7-mg/dL) reduction in LDL-C level was 0.77 (95% CI, 0.71-0.84; P < .001) for statins and 0.75 (95% CI, 0.66-0.86; P = .002) for established nonstatin interventions that work primarily via upregulation of LDL receptor expression (ie, diet, bile acid sequestrants, ileal bypass, and ezetimibe) (between-group difference, P = .72). For these 5 therapies combined, the RR was 0.77 (95% CI, 0.75-0.79, P < .001) for major vascular events per 1-mmol/L reduction in LDL-C level. For other interventions, the observed RRs vs the expected RRs based on the degree of LDL-C reduction in the trials were 0.94 (95% CI, 0.89-0.99) vs 0.91 (95% CI, 0.90-0.92) for niacin (P = .24); 0.88 (95% CI, 0.83-0.92) vs 0.94 (95% CI, 0.93-0.94) for fibrates (P = .02), which was lower than expected (ie, greater risk reduction); 1.01 (95% CI, 0.94-1.09) vs 0.90 (95% CI, 0.89-0.91) for cholesteryl ester transfer protein inhibitors (P = .002), which was higher than expected (ie, less risk reduction); and 0.49 (95% CI, 0.34-0.71) vs 0.61 (95% CI, 0.58-0.65) for proprotein convertase subtilisin/kexin type 9 inhibitors (P = .25). The achieved absolute LDL-C level was significantly associated with the absolute rate of major coronary events (11 301 events, including coronary death or MI) for primary prevention trials (1.5% lower event rate [95% CI, 0.5%-2.6%] per each 1-mmol/L lower LDL-C level; P = .008) and secondary prevention trials (4.6% lower event rate [95% CI, 2.9%-6.4%] per each 1-mmol/L lower LDL-C level; P < .001). CONCLUSIONS AND RELEVANCE: In this meta-regression analysis, the use of statin and nonstatin therapies that act via upregulation of LDL receptor expression to reduce LDL-C were associated with similar RRs of major vascular events per change in LDL-C. Lower achieved LDL-C levels were associated with lower rates of major coronary events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
45 Own result · 16 Own method · 9 Own interpretation · 6 Sources not found · 5 Partly supported · 1 Supported · 1 Not checked yet · 1 No basis given · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“the clinical benefit of the previously recommended use of nonstatin therapies to lower LDL-C is less definitive.7”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Abstract
What the sources say
- Supportedcites [7] 7. Hegele RA, Gidding SS, Ginsberg HN, et al. Nonstatin low-density lipoprotein-lowering therapy and cardiovascular risk reduction. Arterioscler Thromb Vasc Biol. 2015;35(11):2269-2280. source
The Conclusion says statins have the greatest body of randomized-trial evidence for cardiovascular risk reduction. The Abstract describes mixed results for nonstatin therapies and says larger, longer trials were needed for definitive proof of benefit from emerging PCSK9 inhibitors. This supports the comparative claim that the clinical benefit of nonstatin LDL-C-lowering therapies was less definitive, without implying that none had demonstrated benefit. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These data suggest that drugs that ultimately reduce LDL-C level predominantly through upregulation of LDL receptor expression should, barring any off-target adverse effects, lead to clinical benefit in proportion to the degree of LDL-C reduction.64”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
What the sources say
- Partly supportedcites [64] 64. Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272. sourceExperimental — accuracy not yet measured
The Discussion reports that coronary-event reductions in clinical trials were directly related to the magnitude of LDL-C reduction, and the passage on statin treatment (p. 1272) says statins increase LDL-receptor gene expression. The paper does not establish that this relationship applies to drugs generally when they predominantly act through LDL-receptor upregulation, or assess the off-target-effects condition. (LLM, conf=0.82)
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These results are also supported by genetic association and Mendelian randomization studies demonstrating similarly lower rates of cardiovascular outcomes per unit lower LDL-C in patients with loss-of-function variants in the Niemann-Pick C1-Like1 protein (the target of ezetimibe) and in HMG-CoA reductase (the target of statins).62,63”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
What the sources say
- Partly supportedcites [62] 62. Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both. J Am Coll Cardiol. 2015;65(15):1552-1561. sourceExperimental — accuracy not yet measured
The Results (External Validation Analyses; page not available) report similar reductions in coronary heart disease risk per 10 mg/dl lower LDL-C mediated by NPC1L1 and HMGCR polymorphisms. But the Methods describe genetic scores based on selected polymorphisms, not loss-of-function variants in both genes. The Discussion mentions rare NPC1L1 loss-of-function mutations as a separate validation finding; it does not establish the claimed comparison for loss-of-function variants in both genes. (LLM, conf=0.88)
- Not matchedcites [63] 63. Grundy SM. Dyslipidaemia in 2015. Nat Rev Cardiol. 2016;13(2):74-75.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Specifically, each 1-mmol/L reduction in LDL-C was associated with an RR of 0.75 (95% CI, 0.66-0.86;P = .002)in major vascular events”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
What the sources say
- Not checked — no full text of the sourcecites [49] 49. Dayton S, Pearce ML, Hashimoto S, et al. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation. 1969;39-40(supp 2):1- 63. source
- Not checked — no full text of the sourcecites [50] 50. Dorr AE, Gundersen K, Schneider JC Jr, et al. Colestipol hydrochloride in hypercholesterolemic patients. J Chronic Dis. 1978;31(1):5-14. source
- Partly supportedcites [51] 51. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med. 1990;323 (14):946-955. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Major vascular event components (cardiovascular death, acute MI or other acute coronary syndrome, coronary revascularization, and stroke) have been shown to be reduced by therapies that lower LDL-C.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This concept is further supported by human genetic analyses of variants that have been associated with low LDL-C, increased LDL receptors, and decreased coronary heart disease.58,62,63,65”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
What the sources say
- Not matchedcites [58] 58. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203- 212.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [62] 62. Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both. J Am Coll Cardiol. 2015;65(15):1552-1561. sourceExperimental — accuracy not yet measured
The Results (External Validation Analyses; page not provided) associate LDL-C-lowering polymorphisms with lower coronary heart disease risk and describe the hepatic LDL-C receptor as a common final pathway. The paper discusses receptor up-regulation by ezetimibe and statins, but does not establish that the studied variants themselves are associated with increased LDL receptors. (LLM, conf=0.84)
- Not matchedcites [63] 63. Grundy SM. Dyslipidaemia in 2015. Nat Rev Cardiol. 2016;13(2):74-75.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Could not verifycites [65] 65. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014;129(25)(suppl 2):S49-S73. sourceExperimental — accuracy not yet measured
Section 6.2, Critical Question 2 (page not supplied), discusses cumulative exposure to cardiovascular risk factors, but not genetic variants associated with low LDL-C, increased LDL receptors, and reduced coronary heart disease. Searches for those terms in our copy found no passage addressing the claimed genetic analyses. (LLM, conf=0.76)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The observed RR of major vascular events for each of the 5 different established interventions that ultimately act predominantly through upregulation of LDL receptor expression (ie, statins, diet, bile acid sequestrants, ileal bypass, and ezetimibe) was within 0.02 (ie, 2%) of the predicted value from the regression line”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Major vascular event components (cardiovascular death, acute MI or other acute coronary syndrome, coronary revascularization, and stroke) have been shown to be reduced by therapies that lower LDL-C.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Combining the data from all 33 of the aforementioned trials generated the meta-regression line (predicted RR of major vascular events for various levels of LDL-C reduction) in Figure 3, in which each 1-mmol/L reduction in LDL-C was associated with an RR of 0.77 (95% CI, 0.75-0.79) in major vascular events.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Major vascular event components (cardiovascular death, acute MI or other acute coronary syndrome, coronary revascularization, and stroke) have been shown to be reduced by therapies that lower LDL-C.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For the 25 statin trials, each 1-mmol/L (38.7-mg/dL) reduction in LDL-C level was associated with an RR of 0.77 (95% CI, 0.71-0.84;P < .001)for major vascular events (Figure 2A).”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Major vascular event components (cardiovascular death, acute MI or other acute coronary syndrome, coronary revascularization, and stroke) have been shown to be reduced by therapies that lower LDL-C.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“(P = .72for between-group difference with statin therapy)”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Major vascular event components (cardiovascular death, acute MI or other acute coronary syndrome, coronary revascularization, and stroke) have been shown to be reduced by therapies that lower LDL-C.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were 15 trials of interventions that do not reduce LDL-C levels primarily through upregulation of LDL receptor expression (9 trials with fibrates, 3 trials with niacin [1 of which was a multigroup trial that also studied fibrates], and 3 trials with CETP inhibitors).”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 16
- It may state two separate claims as one. 16
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a timeframe during which a clinical benefit of lipid-lowering therapy would not be expected to emerge 10”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Methods
What the sources say
- Partly supportedcites [10] 10. Bulbulia R, Bowman L, Wallendszus K, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals. Lancet. 2011;378(9808):2013-2020. sourceExperimental — accuracy not yet measured
The Results report no statistically significant reduction in major vascular events during the first year of simvastatin treatment, with significant reductions in subsequent years. The Discussion nevertheless notes fewer events in the first year. Neither passage establishes that clinical benefit would not be expected within six months, so the specific timeframe is unsupported. (LLM, conf=0.79)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In terms of the other interventions, the observed RR of 0.94 (95% CI, 0.89-0.99)for major vascular events for niacin was greater (ie, less risk reduction) than the expected RR from meta-regression of 0.91 (95% CI, 0.90-0.92;P = .24),but with 95% CIs that encompass the regression line and z score testing showing no significant difference (P = .24).”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The observed RR of 0.88 (95% CI, 0.83-0.92)for fibrates was lower (ie, greater risk reduction) than the expected RR of 0.94 (95% CI, 0.93-0.94)(P = .02).”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“resulting in approximately 1.3 million person-years of follow-up.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean follow-up was 4.3 years”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, the observed RR reduction in major vascular events was 4% (95% CI, -3% to 10%) in HPS2-Thrive, 11% (95% CI, 1% to 20%) in FIELD, and 8% (95% CI, -8% to 21%) in ACCORD, which were similar to the RR reductions predicted from the meta-regression (7%, 9%, and 0%, respectively).”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“0.88 (95% CI, 0.83-0.92)vs 0.94 (95% CI, 0.93-0.94)for fibrates (P = .02),which was lower than expected (ie, greater risk reduction)”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were 2 trials with PCSK9 inhibitors.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The absolute reduction in LDL-C accounted for 98% of the between-study variability (R 2 value) in the reduction of major vascular events, whereas the percentage reduction in LDL-C only accounted for 79%.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 240 citations were identified and reviewed for eligibility (Figure 1)”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When recalculating the regression slope using non-HDL-C, the RR per 1-mmol/L reduction in non-HDL-C was 0.80 (95% CI, 0.77-0.82),which was similar to the RR with LDL-C reduction.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this systematic review and meta-regression analysis of 49 trials involving 9 different interventions to lower LDL-C that included more than 300 000 patients and approximately 40 000 major vascular events, there was a similar association”
- Also stated in: § 77 Full-text articles assessed for eligibility · plain
“between absolute reductions in LDL-C and lower RRs for major vascular events across therapies that ultimately work predominantly through upregulation of LDL receptor expression, such that each 1-mmol/L (38.7-mg/dL) reduction in LDL-C was associated with an RR of 0.77 (ie, 23% relative reduction) in the risk of major vascular events.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Discussion
plaincorrelationaln = 300,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The therapies classified as acting predominantly via upregulation of LDL receptor expression indeed act predominantly through that mechanism.
- Also stated in: § 77 Full-text articles assessed for eligibility · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were 25 statin trials.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The observed RR of 1.01 (95% CI, 0.94-1.09)associated with CETP inhibitors was significantly greater than the expected RR of 0.90 (95% CI, 0.89-0.91;P = .002)(ie, less risk reduction) with no appreciable clinical benefit in a meta-analysis of the compounds studied to date.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“49 trials, spanning 9 different treatment modalities were included in the meta-regression analysis”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the RR reduction for major vascular events was 6.4% (95% CI, 1%-11%), with an absolute risk reduction of 2% over 7 years.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimated RR of 0.49 (95% CI, 0.34-0.71)associated with PCSK9 inhibitors was numerically lower, but not significantly different, than the expected RR of 0.61 (95% CI, 0.58-0.65),with wide 95% CIs that included the regression line (P = .25).”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Results
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“1.01 (95% CI, 0.94-1.09)vs 0.90 (95% CI, 0.89-0.91)for cholesteryl ester transfer protein inhibitors (P = .002),which was higher than expected (ie, less risk reduction)”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, the data in the present meta-regression analysis raise the possibility that other interventions, especially those that ultimately act predominantly through upregulation of LDL receptor expression, may provide additional options and may potentially be associated with the same relative clinical benefit per each 1-mmol/L reduction in LDL-C.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The therapies classified as acting predominantly via upregulation of LDL receptor expression indeed act predominantly through that mechanism.
In the paper
“A systematic review and trial-level meta-regression analysis of randomized clinical trials that evaluated the effect of therapy to lower LDL-C on cardiovascular outcomes was performed and the results are reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines.9”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Methods
What the sources say
- Not matchedcites [9] 9. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses. Ann Intern Med. 2009;151(4):264-269, W64.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All disagreements were discussed and resolved by consensus.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Methods
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In the earlier trials that did not report LDL-C levels, LDL-C values at baseline and while in the study were estimated from total cholesterol levels (the Supplement provides additional details).”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Methods
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Based purely on LDL-C lowering and given the number of events accrued, the statistical power for their primary end points was only approximately 51% for HPS2-Thrive, 19% for FIELD, and 3% for ACCORD.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Two authors independently extracted and entered data into standardized data sheets and data were analyzed using meta-regression.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“and background therapy has changed, which may account for some of the difference in absolute event rates between trials.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Fourth, the studies included in the analysis were conducted over a span of 51 years”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Third, the data for statins are more extensive than the data for other interventions, with more than 20 000 events from statin trials vs several thousand events each for ezetimibe, niacin, fibrates, and CETP inhibitor trials; several hundred events each for diet, bile acid sequestrants, and ileal bypass trials; and only 2 trials with 111 events during a mean follow-up of 1.2 years for the PCSK9”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Sixth, hazard ratios were not available in all trials and risk ratios were used when they were not.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“First, the meta-analysis was not performed on patient-level data.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“by definition the analyses were at the trial level, examining the association between LDL-C reduction and the RR of major vascular events within a trial.”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper relies on this without support.
The comparative clinical benefit of nonstatin therapies that reduce LDL-C remains uncertain.
“The comparative clinical benefit of nonstatin therapies that reduce low-density lipoprotein cholesterol (LDL-C) remains uncertain.”
The paper relies on this without support.
Major vascular event components (cardiovascular death, acute MI or other acute coronary syndrome, coronary revascularization, and stroke) have been shown to be reduced by therapies that lower LDL-C.
“because all these events have been shown to be reduced by therapies to lower LDL-C.”
The paper relies on this without support.
Fibrates substantially reduce levels of very low-density lipoprotein, an atherogenic particle that contains both cholesterol and triglycerides.
“Fibrates also substantially reduce levels of very low-density lipoprotein, an atherogenic particle that contains both cholesterol and triglycerides.”
The paper relies on this without support.
The therapies classified as acting predominantly via upregulation of LDL receptor expression indeed act predominantly through that mechanism.
“among the trials of statins and established nonstatin therapies that ultimately act predominantly via upregulation of LDL receptor expression”
The paper relies on this without support.
The absolute risk reduction observed in a given trial depends in part on the patient population, the end point, and the duration of follow-up.
“Second, the absolute risk reduction observed in a given trial will depend in part on the patient population, the end point, and the duration of follow-up”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Numerous epidemiological studies, Mendelian randomization studies, and RCTs have consistently demonstrated a log-linear relationship between the absolute changes in plasma LDL-C and the risk of ASCVD [34,45-50].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have shown that dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is an independent risk factor for CHD (3–5).”
From Remnant cholesterol, lipid ratios, and the severity of coronary artery lesions: a retrospective cohort study in patients with coronary heart disease (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The major limitation of this trial was a relatively short duration of follow-up as compared with that in other lipid-lowering trials, in which follow-up periods have averaged approximately 5 years.28”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“elevated low-density lipoprotein cholesterol (LDL-C) maintains its position as the most significant risk factor associated with adverse cardiovascular results.”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LDLR plays a crucial role in the uptake of LDL-C from the circulation by hepatocytes 1,2,7 .”
From Dietary cholesterol activates a Ral-dependent pathway driving LDLR turnover (2026) · cites this paper as [7]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The regulation of LDLR trafficking and turnover is essential for maintaining cholesterol homeostasis and remains a major focus of therapeutic strategies for CVD 1,2,7 .”
From Dietary cholesterol activates a Ral-dependent pathway driving LDLR turnover (2026) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lipid-lowering therapy has transformed the landscape of cardiovascular disease (CVD) prevention, with low density lipoprotein cholesterol (LDL-C) firmly established as a central driver of atherosclerotic CVD (ASCVD) risk [1].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Like LDLC, non-HDLC is treatable with existing lipid-lowering agents and there is a direct, consistent relationship between the magnitude of non-HDLC lowering and cardiovascular risk reduction observed in meta-analyses and trials with statins and other lipid-lowering agents [56,57].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [57]
The cited source says what the claim attributes to it.
In the citing paper
“These observations are in accord with meta-analyses of data from clinical trials of different lipid-lowering interventions, which show consistent clinical benefits per unit reduction in LDL cholesterol.28”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“Therefore, if all ApoB-containing particles have approximately the same atherogenic effect as suggested by this study, then to reduce the risk of cardiovascular events by 20% as can be achieved by lowering LDL-C levels by 40 mg/dL, 3,4 triglyceride levels must be reduced by 5-fold this quantity, or approximately 200 mg/dL, to achieve the same corresponding reduction in ApoB-containing lipoproteins”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [4]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Evidence suggests that atherosclerotic plaques are unlikely to further develop if LDL is at or below 70 mg/dL or 1.8 mmol/L [43].”
From The Effect of Exercise Training on Blood Lipids: A Systematic Review and Meta-analysis (2025) · cites this paper as [43]
Experimental — accuracy not yet measuredIn the citing paper
“In contrast, Mendelian randomization studies do not provide compelling evidence that HDL-C is causally associated with the risk of ASCVD [49,61,62].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > 77 Full-text articles assessed for eligibility
“Ezetimibe was studied in the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) trial 53”
§ Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis > References
“53. The Lipid Research Clinics Coronary Primary Prevention Trial results, 1: reduction in incidence of coronary heart disease.”
Citations
Cites
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Research works printed but not linked: 13
- [7]7. Hegele RA, Gidding SS, Ginsberg HN, et al. Nonstatin low-density lipoprotein-lowering therapy and cardiovascular risk reduction. Arterioscler Thromb Vasc Biol. 2015;35(11):2269-2280.
- [8]8. US Food and Drug Administration. Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Fed Regist. 2016;81(74): 22612-22613.
- [22]22. GISSI Prevenzione Investigators. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction. Ital Heart J. 2000;1(12):810-820.
- [25]25. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994;344(8934):1383-1389.
- [33]33. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER). Lancet. 2002;360(9346): 1623-1630.
- [34]34. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288(23):2998-3007.
- [37]37. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Lancet. 2004;364(9435):685-696.
- [41]41. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA. 2005;294(19):2437-2445.
- [44]44. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study). Lancet. 2006; 368(9542):1155-1163.
- [46]46. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction. Lancet. 2010;376(9753): 1658-1669.
- [50]50. Dorr AE, Gundersen K, Schneider JC Jr, et al. Colestipol hydrochloride in hypercholesterolemic patients. J Chronic Dis. 1978;31(1):5-14.
- [53]53. The Lipid Research Clinics Coronary Primary Prevention Trial results, 1: reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351-364.
- [63]63. Grundy SM. Dyslipidaemia in 2015. Nat Rev Cardiol. 2016;13(2):74-75.
Cited by
Sorted by citations
Items 801–900 of 1,481
First Iranian guidelines for the diagnosis, management, and treatment of hyperlipidemia in adults
Bagherikholenjani, F., Shahidi, S., Vaseghi, G., Ashoorion, V., Sarrafzadegan, N., Siavash, M., Heidarpour, M., Shahidi, S., Sadeghi, M., Mohammadifard, N., et al. (2024) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_318_23 · Cited by 8
Okada, K., Haze, T., Kikuchi, S., Kirigaya, H., Hanajima, Y., Tsutsumi, K., Kirigaya, J., Nakahashi, H., Gohbara, M., Kimura, Y., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64988 · Cited by 6
Monoclonal Anti-PCSK9 Antibodies: Real-World Data
Guidotti, G., Liberati, V., Sorrentino, A., Lotti, E., Crudele, F., Rogolino, A. A., Sammartino, A., Slanzi, M., Gori, A. M., Marcucci, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154543 · Cited by 7
“LDL cholesterol (LDL-C) is one of the main modifiable cardio-vascular risk (CV) factors, since the accumulation of LDL-C and other apo-B-containing lipoproteins is a key event in the initiation and progression of the atherosclerotic process [2,3].”
BackgroundAssociation of LEAF-Q and EDE-QS scores with cholesterol levels in Finnish female athletes
Silvennoinen, J. I. K., Ihalainen, J. K., Valtonen, M., Mjøsund, K., & Sipilä, P. N. (2024) · BMJ Open Sport & Exercise Medicine · doi:10.1136/bmjsem-2024-002050 · Cited by 8
“We could not assess genetic factors that influence cholesterol metabolism, but we did not observe extremely high LDL-C levels ( ≥ 4.9 mmol/L) which would raise concerns of familial hypercholesterolaemia.”
BackgroundInfluentialLDL cholesterol as a causal agent of atherosclerosis
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100728 · Cited by 7
Interpretation and Use of Another Statin Guideline
Greenland, P., & Bonow, R. O. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4950 · Cited by 6
Residual Cardiovascular Risk—Is Inflammation the Primary Cause?
Schade, D. S., & Eaton, R. P. (2018) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2018.81007 · Cited by 6
“All of these approaches have resulted in increasing the hepatic LDL receptor resulting in a reduction in circulating LDL cholesterol, including low cholesterol and saturated fat diets, ileal bypass surgery, intestinal cholesterol blockade by ezetimibe, hepatic cholesterol synthesis reduction by statins, and blockage o…”
BackgroundPractical guide for the use of PCSK9 inhibitors in Portugal
Fontes‐Carvalho, R., Silva, P. M., Rodrigues, E., Araújo, F., Gavina, C., Ferreira, J., & Morais, J. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.07.004 · Cited by 7
“39 645 events.(4) Finally, clinical trials assessing progression of coronary disease by intravascular ultrasound have shown that progression of atherosclerotic plaque can be halted when LDL-C levels are reduced to below 70 mg/dl.”
BackgroundSun, M., Lemaçon, A., Legault, M., Asselin, G., Provost, S., Aschard, H., Barhdadi, A., Zada, Y. F., Valois, D., Mongrain, I., et al. (2021) · The Pharmacogenomics Journal · doi:10.1038/s41397-021-00221-z · Cited by 6
PCSK9 inhibition, LDL and lipopolysaccharides: a complex and "dangerous" relationship
Feminò, R., Feminò, G., Cavezzi, A., & Troiani, E. (2021) · International Angiology · doi:10.23736/s0392-9590.21.04632-0 · Cited by 6
Martinez-Martin, F., Corbella, E., Sarasa, I., Trias, F., Petitbò, D., Liceran, M., Sánchez-Hernández, R. M., Martin, D., Sánchez, A., Arnás, C., et al. (2022) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2022.04.005 · Cited by 6
Grant, J. K., Dangl, M. D., Koester, M., Tegegn, M. B., Knijnik, L., Singh, H., & Orringer, C. E. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.005 · Cited by 6
Nechyporenko, A. V., Tedla, Y. G., Korcarz, C. E., et al. (2022) · Hypertension Research · doi:10.1038/s41440-022-01095-9 · Cited by 6
Patti, G., Cavallari, I., Cesaro, A., Gragnano, F., Riva, L., Fimiani, F., Cuccia, C., Fresco, C., Calabrò, P., Leonardi, S., et al. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.107137 · Cited by 6
Wang, Z., Zhang, X., Qu, Y., Zhang, S., Chen, Y., Chen, X., Qi, X., Liu, P., Liu, S., Jiang, S., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01838-8 · Cited by 7
Peng, B., & Min, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1186992 · Cited by 6
Iuliano, S., Hare, D. L., Vogrin, S., Poon, S., Robbins, J., French, C., & Seeman, E. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.06.004 · Cited by 6
Treating Hypercholesterolemia in Older Adults for Primary Prevention of Cardiovascular Events
Al-Ani, A., Jamil, Y., & Orkaby, A. R. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01139-4 · Cited by 6
“For primary prevention trials, there was a 1.5% lower event rate of vascular or coronary events per each 1-mmol/L LDL level [14].”
InfluentialKlug-entscheiden-Empfehlungen in der Kardiologie
Werdan, K., Baldus, S. E., Frey, N., Nixdorff, U., Kück, K., & Katus, H. A. (2017) · Der Internist · doi:10.1007/s00108-017-0239-7 · Cited by 6
Page, M. M., Bell, D. A., & Watts, G. F. (2019) · Clinical Genetics · doi:10.1111/cge.13685 · Cited by 6
“An approximately 30% reduction in the risk of a first major adverse cardiovascular event is expected irrespective of the baseline LDL-cholesterol or estimated absolute cardiovascular risk in non-FH patients.(51,52) Patients with FH differ somewhat in their response to statin therapy as a result of the mechanism of act…”
BackgroundKobayashi, D., Mizuno, A., Shimbo, T., Aida, A., & Noto, H. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.03.011 · Cited by 6
Puato, M., Zambon, A., Nardin, C., Faggin, E., Pesavento, R., Spinazzè, A., Pauletto, P., & Rattazzi, M. (2021) · Cardiovascular Therapeutics · doi:10.1155/2021/5546800 · Cited by 6
ALERT-LDL: adherence to guidelines in the treatment of patients with dyslipidemia
Bosso, G., Luca, M. D., Alma, G., Carbone, V., Ferrara, F., Fimiani, B., Guarnaccia, F., Iandolo, A., Murolo, S., Olivares, M., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02809-6 · Cited by 6
Bai, Z., Xu, M., Mei, Y., Hu, T., Zhang, P., Chen, M., Lv, W., Lü, C., & Tan, S. (2021) · Biomedicines · doi:10.3390/biomedicines9121783 · Cited by 6
“For over three decades, numerous clinical trials have firmly demonstrated the validity of LDL-C reduction in the prevention of CVD developing [4,54] and LDL-C levels have been accepted as a reliable efficacy endpoint for curative assessment and drug approval [55].”
BackgroundLevintow, S. N., Reading, S. R., Noshad, S., Mayer, S. E., Wiener, C., Eledath, B., Exter, J., & Brookhart, M. A. (2022) · Clinical Epidemiology · doi:10.2147/clep.s361258 · Cited by 6
“Our results highlight a potential gap in care, given this importance of LDL-C monitoring to inform treatment decisions and reduce the risk of future ASCVD events.(4,18) Cholesterol treatment guidelines recommend high-intensity statin use (or maximally tolerated statin therapy) following MI and to consider the addition…”
BackgroundTransatlantic Lipid Guideline Divergence: Same Data But Different Interpretations
Orringer, C. E., Tokgözoğlu, L. S., Maki, K. C., Ray, K. K., Saseen, J. J., & Catapano, A. L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018189 · Cited by 7
Biersteker, T. E., Boogers, M. J., Schalij, M. J., Braun, J., Groenwold, R. H. H., Atsma, D. E., & Treskes, R. W. (2023) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztad035 · Cited by 4
“Therefore, current European guidelines on cardiovascular disease prevention stress the importance of reducing LDL-C and BP levels in patients who underwent CABG.(6) However, a study in 16 646 patients in European Heart Journal - Digital Health (2023) 4, 347–356 https://doi.”
BackgroundInfluentialThe Role of Lipid Metabolism in Dyslipidemias and Atherosclerosis
Janić, M., Yamashita, S., Su, T., et al. (2024) · Metabolites · doi:10.3390/metabo14110596 · Cited by 5
Spina, A., Amone, F., Zaccaria, V., Insolia, V., Perri, A., Lofaro, D., Puoci, F., & Nobile, V. (2024) · Foods · doi:10.3390/foods13233883 · Cited by 5
“Non-pharmacological interventions, and especially naturally-derived ingredients, are well-accepted by consumers due to a better perception of their toxicological and environmentally-friendly profile compared to drugs [53].”
Sayed, A. A., Afify, H. M. A., Munir, M., ElGarhy, I., Shazly, O., ElRefaei, M., Ahmed, S., Amin, A. M., Amine, O. C., & Elgendy, I. Y. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15315 · Cited by 8
Labinaz, A., Yao, R., Hosseini, F., Turgeon, R. D., Marchand, M., Brunham, L. R., Hawkins, N. M., Wong, G. C., Mancini, G. B. J., & Fordyce, C. B. (2025) · CJC Open · doi:10.1016/j.cjco.2025.06.021 · Cited by 5
Diagnosis and Management of Statin-Associated Muscle Symptoms
Cha, J., & Hong, S. J. (2025) · Korean Circulation Journal · doi:10.4070/kcj.2025.0285 · Cited by 5
Smart, N. A., Wood, G., Pearson, M. J., Dieberg, G., van der Touw, T., & Kostner, K. (2025) · Journal of science and medicine in sport · doi:10.1016/j.jsams.2025.11.004 · Cited by 6
Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Irshad, S. M., Raheem, R., Junais, E., John, A. A., Rassal, R. Y., Kumari, R., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05515-3 · Cited by 5
“The identification of LDL-C as an atherogenic risk marker has proven its value as a therapeutic target that helps decrease cardiovascular death rates and morbidity [3].”
Therapeutic Inertia in Lipid-Lowering Treatment: A Narrative Review
Vatri, M., Faggiano, A., Angelino, E., Ambrosetti, M., Faggiano, P. M., & Fattirolli, F. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031075 · Cited by 9
“This established evidence reinforces that the persistent gap in LDL-C target attainment is less a matter of therapeutic uncertainty and more the consequence of implementation failures and delayed treatment intensification [3,4].”
Optimal Medical Therapy for Stable Ischemic Heart Disease in 2024
Abrahams, T., Nicholls, S. J., & Nelson, A. J. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.12.005 · Cited by 5
Deza, S., Colina, I., Beloqui, Ó., Monreal, J. I., Martínez-Chávez, E., Maroto‐García, J., Mugueta, C., González, Á., & Varo, N. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.117897 · Cited by 5
Cancro, F. P., Bellino, M., Silverio, A., Maio, M. D., Esposito, L., Palumbo, R., Manna, M., Formisano, C., Ferruzzi, G. J., Vecchione, C., et al. (2024) · Translational Medicine UniSa · doi:10.37825/2239-9747.1058 · Cited by 5
Kannenkeril, D., Bosch, A., Kolwelter, J., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02556-6 · Cited by 5
“Several studies have provided strong support for the concept that lower LDL-C levels are the key to achieve better outcomes[30, 31], and that it is possible to achieve these on top of statin therapy (despite of the much debated potential “pleiotropic” effects of statins) [3, 32].”
Piccirillo, F., Lanciotti, M., Nusca, A., Frau, L., Spanò, A., Liporace, P., Ussia, G. P., & Grigioni, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052103 · Cited by 6
“Significant efforts have been made in primary prevention to reduce cardiovascular risk factors by promoting a healthy lifestyle and the use of drugs that help to prevent plaque formation and progression [2].”
Patti, G., Grisafi, L., Azzolina, D., Cumitini, L., D’Amario, D., & Mennuni, M. G. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120433 · Cited by 5
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
Nelson, A. J., Puri, R., Brennan, D. M., Anderson, T. J., Cho, L., Ballantyne, C. M., Kastelein, J. J. P., Köenig, W., Kassahun, H., Somaratne, R. M., et al. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100091 · Cited by 5
Cequier, A. R., Arrarte, V., Campuzano, R., Castro, A., Cordero, A., Olmo, M. R. F., García–Moll, X., Gómez‐Doblas, J. J., de Sá, E. L., Núñez, J. E., et al. (2020) · REC CardioClinics · doi:10.1016/j.rccl.2020.10.017 · Cited by 5
Langlois, M. R., & Briers, P.-J. (2021) · Biochemia Medica · doi:10.11613/bm.2022.010704 · Cited by 11
Cholesterol and its biological significance. Atherosclerosis. Statin therapy (Part 1)
Vasiliev, A. P., & Streltsova, N. N. (2022) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2021-36-4-27-35 · Cited by 5
“Повышенный риск сердечно-сосудистых заболеваний и преждевременной смерти у лиц с семейной ГХС, обусловленной дефицитом рецепторов ХСЛПНП, обычно рассматривается как убедительный аргумент в пользу холестериновой теории атеросклероза [22, 23].”
Loaiza-Betancur, A. F., Gómez‐Tomás, C., Blasco, J., et al. (2022) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002076 · Cited by 5
The pattern of dyslipidemia among Somali type 2 diabetic patients: a cross-sectional study
Alıcı, G., & Genç, Ö. (2022) · European journal of medical research · doi:10.1186/s40001-022-00882-x · Cited by 5
“As a result, LDL-C is still the primary target of lipid-lowering medication [38].”
BackgroundPinsdorf, D., Messiha, D., Petrikhovich, O., Bahar, M., Steinmetz, M., Mahabadi, A. A., Dykun, I., Lortz, J., Rassaf, T., & Rammos, C. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.05.100 · Cited by 5
Maliwal, D., Pissurlenkar, R. R. S., & Telvekar, V. N. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2222173 · Cited by 5
“From time unknown hypercholesterolemia has been contem-plated as a self driven risk factor for CVD. Lowering the low-density lipoprotein cholesterol (LDL-C) has significant impact on the reduction of the cardiovascular risk has been seen in clinical trials (Silverman et al., 2016).”
BackgroundCemin, R., Casablanca, S., Ermacora, D., & Daves, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134422 · Cited by 5
Lis, A., Lis, P., Łowicka, W., Grabarczyk, M., Wita, M., Żarczyński, P., Żarczyńska, M., & Haberka, M. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080329 · Cited by 5
“Unfortunately, despite widely available evidence on the effectiveness of statin use [30] to lower LDL-C in this group of patients, many of them fail to achieve the appropriate therapeutic goal.”
BackgroundDu, X., Ding, J., Ma, X., Yang, R., Wang, L., & Sha, D. (2023) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-023-02957-0 · Cited by 5
Luo, F., Lin, Y., Zhang, X., Li, Y., Su, L., Zhou, S., Xu, R., Gao, Q., Chen, R., Guo, Z., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad354 · Cited by 8
Liu, C., Dai, M., Tian, K., Zhou, S., Luo, L., Zeng, Z., Yan, X., Xiao, Y., Wang, Y., Deng, R., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1286286 · Cited by 5
Gylling, H. K., Öörni, K., Nylund, L., Wester, I., & Simonen, P. P. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.01.022 · Cited by 5
Chun, E., Crete, A., Neal, C., Joseph, R., & Pojednic, R. M. (2024) · Healthcare · doi:10.3390/healthcare12060676 · Cited by 5
“Decreases in LDL cholesterol can help reduce major vascular events [20], and having low hsCRP, defined as 2 mg/L, can have protective effects against stroke and coronary heart disease [21].”
BackgroundAssociations between remnant cholesterol levels and mortality in patients with diabetes
Pan, D., Xu, L., Zhang, L., Shi, D.-Z., & Guo, M. H. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i4.712 · Cited by 5
Burger, P. M., Bhatt, D. L., Dorresteijn, J. A. N., Koudstaal, S., Mosterd, A., Martens, F. M. A. C., Steg, P. G., Visseren, F. L. J., for the REDUCE-IT Investigators, Ladner, J., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae030 · Cited by 5
“30 , 31 Second, in low-risk patients from REDUCE-IT, their elevated triglyceride level may be ( one of) the main driver( s) of their CVD risk, and lowering triglycerides may therefore have a relatively large impact on their risk of future events.”
The Economic Burden of Atherosclerotic Cardiovascular Disease in Italy
Mennini, F. S., Scortichini, M., Colivicchi, F., Maggioni, A. P., & Sciattella, P. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01365-z · Cited by 5
Lim, Y. L., Tan, R., Poh, K. K., & Wang, X. J. (2025) · Value in Health Regional Issues · doi:10.1016/j.vhri.2024.101067 · Cited by 5
Perakakis, N., Funk, A. M., Kolb, T., Jonas, S., Hellerhoff, I., Tam, F. I., Bornstein, S. R., Chavakis, T., Mirtschink, P., & Ehrlich, S. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.01.014 · Cited by 5
Evolving Approaches for Statins in Primary Prevention
Návar, A. M., & Peterson, E. D. (2016) · JAMA · doi:10.1001/jama.2016.15094 · Cited by 5
Statins for primary prevention of cardiovascular disease
Otto, C. M. (2016) · Heart · doi:10.1136/heartjnl-2016-310959 · Cited by 5
Prioritising Risk Factors for Type 2 Diabetes: Causal Inference through Genetic Approaches
Wittemans, L. B. L., Lotta, L. A., & Langenberg, C. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1009-1 · Cited by 7
Benestad, B., Júlíusson, P. B., Siegfried, W., Lekhal, S., Småstuen, M. C., Hertel, J. K., Agosti, F., Marazzi, N., Hjelmesaeth, J. S., & Sartório, A. (2018) · Acta Paediatrica · doi:10.1111/apa.14542 · Cited by 5
“Nonetheless, elevated LDL-C is a major causal risk factor for cardiovascular disease in adults, and it has been demonstrated that lowering LDL-C reduces the risk of cardiovascular disease (7).”
BackgroundWang, S., Hu, X., & Pan, Y. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1140-2 · Cited by 5
Hsu, C., Chen, W., Chen, H., Tsai, H., & Hsiao, F. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13299 · Cited by 5
Statins in Healthy Adults: A Meta-Analysis
Sandwith, L., & Forget, P. (2021) · Medicina · doi:10.3390/medicina57060585 · Cited by 5
Martin, G. J., Teklu, M., Mandieka, E., & Feinglass, J. M. (2022) · Cardiology Research and Practice · doi:10.1155/2022/7537510 · Cited by 5
“Progressively lower LDL-C levels have continued to show incremental benets [3] including the utility of nonstatin approaches [4].”
BackgroundŠuštar, U., Grošelj, U., Khan, S. A., Shafi, S., Khan, I., Kovač, J., Bizjan, B. J., Battelino, T., & Sadiq, F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.983283 · Cited by 5
“Statin therapy substantially reduced the CVD risk in patients with high LDL-C levels (Silverman et al., 2016).”
BackgroundWard, N. C., Reid, C. M., & Watts, G. F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1060252 · Cited by 5
Recent updates in dyslipidemia management: perspectives in stroke-specific situation
Seo, W., Hosseini, M. B., Bang, O. Y., & Liebeskind, D. S. (2020) · Precision and Future Medicine · doi:10.23838/pfm.2020.00009 · Cited by 5
Opinion paper: Is the Friedewald equation obsolete?
Jialal, I., & Winter, W. E. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.12.032 · Cited by 5
Empleo del ácido bempedoico en los pacientes con dislipemia. Una aproximación práctica
Escobar, C., Barrios, V., Ariza, A., Campuzano, R., Martínez, J. M. G., & Mostaza, J. M. (2021) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(21)00005-4 · Cited by 5
Battaggia, A., Scalisi, A., & Donzelli, A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1428188 · Cited by 5
Mancini, G. B. J., & Hegele, R. A. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.02.027 · Cited by 5
Barrios, V., Escobar, C., Anguita, M. P., Arrarte, V., Ruíz, R. C., Cosı́n-Sales, J., Cabello, M. I. E., Martínez, J. M. G., Guijarro, C., Mostaza, J. M., et al. (2021) · REC CardioClinics · doi:10.1016/j.rccl.2021.02.006 · Cited by 5
Multitrait genetic-phenotype associations to connect disease variants and biological mechanismsPreprint
Julienne, H., Laville, V., McCaw, Z. R., He, Z., Guillemot, V., Lasry, C., Ziyatdinov, A., Vaysse, A., Lechat, P., Ménager, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.172999 · Cited by 5
Zheng, W., Zhang, J., Huang, Y., Wang, S., Gao, X., Yang, Z., Zong, Y., & Yang, Z. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00694-6 · Cited by 4
Reed, S. D., Sutphin, J., Gonzalez, J. M., Wallace, M. J., Stephenson, J. J., Electricwala, B., Bosworth, H. B., & Pagidipati, N. (2025) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.124.011804 · Cited by 4
“1,8,9 Nevertheless, these lipid-lowering therapies (LLTs) are underutilized, and patients who initiate therapy often discontinue.”
Kuang, J. C., Hao, L., Zhang, M., & Yang, Z. (2025) · MedComm · doi:10.1002/mco2.70451 · Cited by 7
Reynolds, A. N., Hood, F. E., Wilson, R., Ross, A. B., Neumann, S., Turner, R. M., Iosua, E. E., Katare, R., Shahin, A., Kok, Z.-Y., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-074278 · Cited by 5
Volkova, A., Shulgin, B., Helmlinger, G., Peskov, K. V., & Sokolov, V. V. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1242845 · Cited by 4
Fang, Y., Wu, H., Liang, X., Li, T., Jia, R., Dong, Y., Zheng, Y., Wang, Q., & Li, L. (2024) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-24-146 · Cited by 4
Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study
Liu, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1353848 · Cited by 5
Time to benefit of intensive lipid lowering therapy in individuals with cardiovascular disease
Li, L., Huang, C., Liu, W., Li, J., Geru, A., Chen, X., Jiang, S., Fang, Y., Foo, R., Chan, M. Y., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.09.014 · Cited by 5
Repurposing statin treatment for the prevention of gallstone disease.
Rønborg, S. N., Qayyum, F., Lauridsen, B., Frikke-Schmidt, R., Nordestgaard, B., Christoffersen, M., & Tybjærg-Hansen, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120507 · Cited by 5
Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease
Wójcik, C. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1376570 · Cited by 4
“All supporting the notion that ‘lower is better’ [10].”
BackgroundThe ever-growing burden of cardiovascular disease
Yılmaz, M. B., & Güneş, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822258-4.00008-0 · Cited by 4
Simonen, P. P., Arte, E., & Gylling, H. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd8040036 · Cited by 4
Leopold, S., & Zachariah, J. P. V. (2021) · Pediatric Annals · doi:10.3928/19382359-20210218-01 · Cited by 4
Superando las barreras en el abordaje del paciente crónico
Molinera, V. G., Divisón, J. A., Rodríguez, Á. D., & Vargas, M. F. (2022) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2022.101874 · Cited by 4
Bempedoic Acid and Statins in Lipid-Lowering Strategy: Which Came First, the Egg or the Chicken?
Natale, F., Molinari, R., Franzese, R., Mollo, N., & Cimmino, G. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3020024 · Cited by 4
“The relationship between low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular events, such as myocardial infarction and stroke, has been confirmed by epidemiological, clinical, and Mendelian studies [1,2].”
BackgroundHuang, H., Kuang, Z., Mo, R., Meng, M., Cai, Y., & Ni, X. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1227450 · Cited by 4
“However, the positive correlation of Flavonifractor with LDL-C was unexpected, considering that elevated LDL-C is a well-established risk factor for cardiovascular disease (Silverman et al., 2016).”
BackgroundBaki, K. A., Akilimali, P. Z., Mwamba, D., Komakech, A., & Magné, J. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21111450 · Cited by 4
Liu, L., Deng, Y., Li, L., Yang, X., Yin, Z., & Lai, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310696 · Cited by 4
Liu, J., Teng, T.-Q., Li, Z., Hu, F.-W., Sha, W., Shen, C., Xia, Y., Zhang, Y., & Li, L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1471479 · Cited by 4
Association of LDL ‐C/ HDL ‐C Ratio With Hyperuricemia: A National Cohort Study
Zhang, Y., Liu, X., Luo, D., Chen, B., Lai, C., He, C., Luo, Y., Ding, H., & Li, S. (2025) · Clinical and Translational Science · doi:10.1111/cts.70122 · Cited by 4
Fu, L., Liu, Q., Cheng, H., Zhao, X., Xiong, J., & Mi, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038857 · Cited by 4
Hypertension and cardiometabolic disorders appear 5–10 years earlier in women with pre-eclampsia
Janssen, E. B. N. J., Ghossein‐Doha, C., Hooijschuur, M. C. E., Mulder, E., Schiffer, V. M. M. M., Alers, R., Jorissen, L. M., Jansen, G., Kroon, A. A., Brugts, J. J., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf187 · Cited by 7
Metadata
- Authors
- Silverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Wayne State University (US)
- The University of Texas Southwestern Medical Center (US)
- TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
- Corresponding author
- Sabatine, Marc S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-09-27
- Volume
- 316
- Issue
- 12
- Pages
- 1289
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2465758073
- Cited by
- 1,483
- References
- 79
- Citations by year
- 2026: 111 · 2025: 163 · 2024: 182 · 2023: 202 · 2022: 152 · 2021: 151 · 2020: 170 · 2019: 152 · 2018: 115 · 2017: 70 · 2016: 13
- FWCI
- 23.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (T32HL007604)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- LDL cholesterol lowering, cardiovascular risk reduction, statins, non-statin lipid-lowering therapy, LDL receptor upregulation, ezetimibe, bile acid sequestrants, ileal bypass, dietary intervention, myocardial infarction, major vascular events, coronary revascularization, stroke, cardiovascular mortality, acute coronary syndrome, LDL cholesterol targets
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Niacin, Receptors, LDL, Up-Regulation, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
